Report of Foreign Issuer (6-k)
August 24 2015 - 10:44AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
August
24, 2015
________________
NOVO NORDISK A/S
(Exact
name of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
Form 20-F [X]
|
Form 40-F [ ]
|
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-________
Novo
Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 24 August 2015 – On 30 April 2015, Novo Nordisk initiated
a share repurchase programme in accordance with the provisions of the European Commission’s regulation no 2273/2003 of 22
December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of
up to DKK 17.5 billion to be executed during a 12-month period beginning 30 January 2015.
Under the programme initiated 30 April 2015, Novo Nordisk will repurchase B shares for an
amount up to DKK 9.3 billion in the period from 30 April 2015 to 27 October 2015.
Since the announcement as of 17 August 2015, the following transactions have been made under
the programme:
|
Number of
B shares |
Average
purchase price |
Transaction
value, DKK |
Accumulated, last announcement |
14,180,200 |
|
5,425,477,950 |
17 August 2015 |
190,000 |
391.52 |
74,388,401 |
18 August 2015 |
188,000 |
396.53 |
74,547,132 |
19 August 2015 |
200,000 |
394.30 |
78,859,880 |
20 August 2015 |
215,000 |
386.51 |
83,100,016 |
21 August 2015 |
210,000 |
371.77 |
78,071,259 |
|
|
|
|
Accumulated under the programme |
15,183,200 |
|
5,814,444,638 |
Transactions related to Novo Nordisk’s incentive programmes have resulted in a net
sale by Novo Nordisk of 4,060 B shares in the period from 17 August 2015 to 21 August 2015. The shares in these transactions were
not part of the Safe Harbour repurchase programme.
Page 2 of 2
With the transactions stated above, Novo Nordisk owns a total of 34,951,571 B shares of DKK
0.20, corresponding to 1.3% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,600,000,000
including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 17.5 billion during a
12-month period beginning 30 January 2015. As of 21 August 2015, Novo Nordisk has repurchased a total of 26,361,104 B shares equal
to a transaction value of DKK 9,514,444,309.
Novo Nordisk is a global healthcare company with more
than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also
enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in
Denmark, Novo Nordisk employs approximately 39,700 people in 75 countries and markets its products in more than 180 countries.
Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For
more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube
Further information
Media: |
|
|
Anne Margrethe Hauge |
+45 3079 3450 |
amhg@novonordisk.com |
|
|
|
Investors: |
|
|
Peter Hugreffe Ankersen |
+45 3075 9085 |
phak@novonordisk.com |
Daniel Bohsen |
+45 3079 6376 |
dabo@novonordisk.com |
Melanie Raouzeos |
+45 3075 3479 |
mrz@novonordisk.com |
Frank Daniel Mersebach (US) |
+1 609 235 8567 |
fdni@novonordisk.com |
Novo Nordisk A/S
|
Novo Allé
2880 Bagsværd
Denmark
|
Telephone:
+45 4444 8888
|
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
|
|
|
|
|
|
|
Company announcement No 50 / 2015
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: August 24,
2015
|
Lars Rebien Sørensen,
Chief Executive Officer
|
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Apr 2024 to May 2024
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From May 2023 to May 2024